spacer
home > ict > autumn 2019 > the spirit of radical integration
PUBLICATIONS
International Clinical Trials

The Spirit of Radical Integration





Patricia Leuchten, Founder and CEO of The Avoca Group, asked people at a recent pharmaceutical industry conference to raise their hands if they felt their company was ‘pretty good’ − not great, just pretty good − at dealing with the risks inherent in the clinical trial process.

Not a single hand went up.

Her goal is to one day ask again and see every hand raised. Leuchten’s passion, and Avoca’s mission, is for an industry that now struggles to manage risks and design quality into clinical trials to develop a more proactive mindset and overcome communication gaps in bringing life-changing products to patients. As she puts it, “It’s the difference between putting out fires and preventing fires”. Clinical trials are, of course, never free of risks, especially with increasingly complex therapies, trial designs, and operating models. They all contain elements of the unknown that no amount of preparation can completely erase. However, risks can be proactively identified, managed, and mitigated, and that’s where Avoca comes in.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the company


The Avoca Group is a life science consulting firm dedicated to improving quality and compliance in clinical trial execution. Since 2011, the AQC, a collaborative of over 100 pharma, biotech, CRO, and clinical service provider companies, has led the industry in developing practical solutions for improving quality and execution in clinical trials. Companies benefit from Avoca’s insightful research, deep subject matter expertise, industry-leading approaches, and technology. Avoca offers platforms and tailored solutions to help clinical research companies increase quality, ensure compliance, and improve efficiency so that medicines can reach patients faster.
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

SCOPE Summit for Clinical Ops Executives

18-21 February 2020, Hyatt Regency, Orlando, Florida, US

Celebrating its 11th successful year, SCOPE Summit 2020 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 20 different conferences, 3 plenary keynote sessions, the annual Participant Engagement Awards, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement